Analytics

Equity Analytics

Equity Analytics/ONC

ONC

BeOne Medicines AG

Healthcare - US

BeOne Medicines Ltd. (ONC) is a global oncology company that discovers, develops and commercializes innovative cancer treatments spanning hematology and solid tumors; its marketed products include BRUKINSA (zanubrutinib), a second-generatio…

HQ: Basel, PA, Switzerlandbeonemedicines.com

USD416.54+0.14%vs prev. close

Performance

+2.35%

+18.51%

+19.87%

+13.08%

YTD

+37.11%

Valuation

P/E

53.4

EPS TTM

7.80

Dividend yield

—

Size and risk

Market cap

$47.6B

Beta

0.63

Next earnings

Report date

EPS estimate

Revenue estimate

Peer comparison

BeOne Medicines
ONC
Biotechnology
Mkt cap (USD bn)
47.6
P/E
53.4
Div yld
—
1W
+2.4%
1M
+18.5%
3M
+19.9%
6M
+42.0%
1Y
+13.1%
YTD
+37.1%

Company	Ticker	Industry	Mkt cap (USD bn)	P/E	Div yld	1W	1M	3M	6M	1Y	YTD
BeOne Medicines	ONC	Biotechnology	47.6	53.4	—	+2.4%	+18.5%	+19.9%	+42.0%	+13.1%	+37.1%

Subscribe to Equity Analytics to compare ONC with its closest peers

Sector-matched peer set with side-by-side valuation, dividend and performance over every window.

View plans

Ask Ashenden

Ask, then keep asking: it follows the conversation for 30 minutes, grounded in Ashenden research.

Built on Ashenden research and our own data. Answers are AI-generated: they can be wrong or incomplete — check anything you would act on.

Equity Analytics

ONC

Price history

Next earnings

Peer comparison

Equity Analytics

ONC

Price history

Next earnings

Peer comparison